Walk past any urology clinic in a major US city and you are likely to see advertisements for low-intensity shockwave therapy, sometimes branded as “GAINSWave,” promising drug-free, surgery-free restoration of natural erections. The reality is more nuanced. Shockwave therapy for ED is an active area of clinical research with promising mechanistic plausibility but inconsistent published efficacy, and it remains classified as investigational by the American Urological Association. The treatment is widely available, expensive, and not covered by insurance, which makes understanding what it does and does not do worthwhile before committing thousands of dollars.
How Low-Intensity Shockwave Therapy Works
Low-intensity shockwave therapy (LiSWT) uses focused acoustic pulses — at energy levels far below those used in lithotripsy for kidney stones — applied externally to the penile shaft and crura. The proposed mechanism is angiogenesis: the mechanical energy stresses the vascular endothelium, which upregulates vascular endothelial growth factor (VEGF) and recruits endothelial progenitor cells, theoretically improving the cavernosal microcirculation that drives erections.
The mechanism is plausible. Animal models demonstrate increased capillary density, restored neuronal markers, and improved erectile responses after LiSWT. Whether the same effect translates to durable clinical benefit in humans is less clear. The therapy is distinct from radial pressure wave therapy (often marketed alongside it), which uses different physical principles and has weaker evidence.
Indications
The strongest theoretical rationale for shockwave therapy is in men with vasculogenic erectile dysfunction — that is, ED driven by atherosclerosis or endothelial dysfunction. Men with mild to moderate vascular ED who respond to PDE5 inhibitors but want to reduce or stop oral therapy are the population most often treated. Men with severe ED, neurogenic ED, post-prostatectomy ED, or psychogenic ED are less likely to benefit based on existing data.
The therapy is being studied as well in men with Peyronie’s disease, although evidence there is even thinner than in ED.
How the Treatment Is Done
Protocols vary widely, which is part of why evidence is hard to interpret. A typical protocol delivers 3,000 to 5,000 pulses per session at low energy density (0.09 to 0.25 mJ/mm²), divided across 4 to 12 sessions over 4 to 8 weeks. Sessions last 15 to 30 minutes, are performed in office, and are generally painless — most men describe a tingling or tapping sensation. No anesthesia is needed.
The device is held against multiple anatomic sites along the penile shaft and crura, with the goal of treating the full vascular bed. There is no recovery time and patients typically resume normal activity immediately, including sex.
What the Evidence Actually Shows
Several small randomized trials and meta-analyses suggest a modest improvement in erection scores, particularly in men with mild to moderate vasculogenic ED. A frequently cited 2019 meta-analysis in PMC reported a clinically meaningful but modest improvement in IIEF-EF scores compared to sham. Effect sizes are smaller than those produced by PDE5 inhibitors, the durability beyond 6 to 12 months is uncertain, and there is significant heterogeneity in protocols, devices, and patient selection across studies.
The AUA’s 2018 guideline (and subsequent updates) explicitly classifies shockwave therapy for ED as investigational, recommending it be performed only within clinical trials or with informed consent acknowledging the experimental nature of the treatment. The European Association of Urology has been somewhat more permissive but still describes the evidence as preliminary. The bottom line: there is signal, the safety profile is favorable, but it is not yet a proven therapy.
Risks and Side Effects
Compared to surgery or pharmacotherapy, the safety profile is favorable. Reported side effects include transient penile bruising, mild discomfort, petechiae, and rare hematomas. Serious adverse events are exceptionally uncommon. The bigger risk is opportunity cost — money and time spent on shockwave that does not produce results, when established therapy might have.
Alternatives
For most men with ED, oral PDE5 inhibitors remain the first-line treatment with high response rates and very low cost (see our ED medications comparison). Men who fail oral therapy have second-line options including vacuum devices and intracavernosal injection. Refractory cases benefit from a penile implant. Lifestyle interventions — weight loss, exercise, treating sleep apnea, smoking cessation — produce measurable improvement in vascular ED and are essentially free. Testosterone replacement therapy is appropriate when hypogonadism is documented.
Cost and What to Expect at a Clinic
Shockwave therapy is not covered by insurance in the US. Cash prices typically run $400 to $700 per session, with full protocols of 6 to 12 sessions costing $2,400 to $7,000 or more. Some clinics bundle “membership” packages or maintenance schedules at higher total cost. Telemedicine companies and franchised “GAINSWave” providers tend to charge at the upper end of the range.
Selecting a clinic that uses an FDA-cleared focused-shockwave device (rather than a radial pressure wave device, which is less rigorously studied for ED), follows a published protocol, and is run by or supervised by a urologist is more likely to produce a meaningful trial of therapy. For broader cost considerations, see the healthcare costs guide.
When to Consider It
Men with mild to moderate vasculogenic ED who want to reduce or eliminate PDE5 inhibitor use, who can absorb the cost, and who understand the experimental nature of the treatment are the realistic candidates. Men with severe ED, post-prostatectomy ED, or refractory ED are less likely to benefit and may be better served by a urology evaluation for second- or third-line therapy. Discussing shockwave with a urologist — not just a wellness clinic salesperson — helps set expectations realistically. For the broader landscape of related conditions, the medical conditions guide provides additional context.
Frequently Asked Questions
Is shockwave therapy FDA-approved for ED?
No. Specific shockwave devices have FDA clearance for other indications (such as kidney stone fragmentation or musculoskeletal pain) but no shockwave device is FDA-approved for the treatment of erectile dysfunction. Use for ED is off-label.
How long do the results last?
Published trials with the longest follow-up suggest meaningful benefit at 6 to 12 months in responders. Durability beyond two years is poorly characterized. Some clinics offer maintenance treatments every 12 to 24 months.
Will I still need ED pills after shockwave?
Many men continue PDE5 inhibitors after shockwave therapy at lower doses or with reduced frequency. Complete drug independence is uncommon. Trials have generally measured improvement in erection scores rather than freedom from medication.
How is shockwave different from “GAINSWave”?
GAINSWave is a marketing brand for a network of clinics that offer low-intensity shockwave therapy; it is not a distinct treatment. Some GAINSWave clinics use focused shockwave devices and others use radial pressure wave devices. Asking about the specific device and protocol matters more than the brand name.
The Bottom Line
Shockwave therapy for ED is a genuinely interesting investigational treatment with a favorable safety profile and modest published efficacy in mild to moderate vascular ED. It is not a replacement for proven therapies, it is expensive, and the evidence base is still evolving. Men considering it should have realistic expectations, ensure their clinic uses a focused-shockwave device with a published protocol, and view the spend as a trial of an experimental therapy rather than a standard of care.